RFK Jr. Proposes Medicare GLP-1 'Framework' (April 2026): Glucose Monitors First, Coverage Second

Verified April 16, 2026: HHS Secretary Robert F. Kennedy Jr. said on CBS News (interview aired April 15) that he is considering a formal regulatory framework for Medicare and Medicaid to cover GLP-1 weight loss drugs — but only for patients who have already tried and failed glucose monitors (about $80/month), diet changes, and exercise. Kennedy repeated the position in testimony before the House Ways and Means Committee earlier today. This is not blanket Medicare coverage. It is a step-therapy gate layered on top of the Medicare GLP-1 Bridge Demonstration already launching July 2026 at $50/month. If you are on Medicare or Medicaid, this changes the timeline for how and when you might qualify — see our insurance coverage lookup for plan-specific guidance, or compare all 40 telehealth providers that offer self-pay GLP-1s today.

What Kennedy Actually Said

In the CBS interview, Kennedy said he would prefer patients try other interventions first — citing continuous glucose monitors (CGMs) as a $80/month alternative he called "very, very effective" and "extraordinarily effective in helping people lose weight and avoid diabetes." He also emphasized "health regimens — including, particularly, change in diet, but also exercise."

The framing is consistent with Kennedy's Make America Healthy Again executive order and with CMS's January 2026 BALANCE Model — a voluntary CMS Innovation Center demonstration that ties GLP-1 coverage to comprehensive lifestyle intervention. Kennedy's proposed framework would formalize the same logic into a standing Medicare/Medicaid rule.

On April 15, five Senate Democrats sent a letter urging Kennedy to re-issue the Biden-era Medicare/Medicaid GLP-1 coverage rule (originally proposed November 2024, shelved by the Trump administration in April 2025). Kennedy's framework is a response to this pressure — but with step-therapy gates the Biden rule did not contain.

The 'Exhaust Other Options' Gate — Decoded

Step therapy is a pre-existing tool in commercial insurance. It means: before an insurer will pay for a more expensive drug, the patient must first try cheaper or less aggressive interventions and document that they didn't work. Kennedy's framework would extend this to federal GLP-1 coverage.

The likely step ladder (based on Kennedy's statements)

• •Step 1 — Continuous glucose monitor (~$80/month). Dexcom G7, Abbott Libre 3, or similar. Kennedy cited these as the primary alternative. Clinical evidence on CGMs for non-diabetic weight loss is weaker than for GLP-1s, but costs are an order of magnitude lower.
• •Step 2 — Structured diet program. Likely means documented enrollment in an evidence-based lifestyle intervention (the CDC's National DPP Lifestyle Change Program is the existing Medicare-covered template).
• •Step 3 — Structured exercise program. Medicare already covers the Diabetes Self-Management Training (DSMT) benefit — the framework would likely add a weight-specific analog.
• •Step 4 — Documented failure of steps 1-3 to meet a clinical weight-loss threshold (not yet defined).
• •Step 5 — GLP-1 coverage approved at the Medicare GLP-1 Bridge price of $50/month copay.

How This Stacks with Already-Announced Programs

The four programs don't overlap cleanly. If the Kennedy framework is formalized, the most likely path is a layered system: the Bridge Demonstration runs as-is through 2028 (covering the ~3.4M already-qualified beneficiaries), while the new framework applies to everyone else — meaning the broader Medicare/Medicaid population would face step therapy. The Bridge becomes the legacy pilot, the framework becomes the standing rule.

What You Should Do Right Now

If you're on Medicare Part D and want GLP-1 coverage: The Medicare GLP-1 Bridge is unaffected by Kennedy's framework and launches July 1, 2026 at $50/month. Your doctor can start the BMI + comorbidity documentation now. Do not wait for the framework.

If you're on Medicaid: Your state's implementation varies. Compare Medicaid GLP-1 coverage by state — 19 states cover at least one GLP-1 for weight loss today; 32 do not. The Kennedy framework, if formalized, would create a federal floor — but existing state programs would likely continue in parallel for months.

If you want to skip the step-therapy wait entirely: Self-pay telehealth providers are unaffected by any of this. Compounded tirzepatide starts at $149/month via our top-ranked self-pay programs. Brand Wegovy via NovoCare direct is $349/month. Our 7-question quiz matches you to a program in under 60 seconds.

If you're already on a GLP-1: Nothing changes for existing users. Kennedy's framework is proposed for new Medicare/Medicaid authorizations — not continuation of existing prescriptions.

Frequently Asked Questions

Is Kennedy's framework law yet?

No. Kennedy told CBS News he is "considering" a regulatory framework. No notice of proposed rulemaking has been published in the Federal Register. Formal rulemaking typically takes 6-12 months minimum.

Does this affect the Medicare GLP-1 Bridge launching in July?

No. The Bridge Demonstration is a CMS Innovation Center pilot with its own legal authority. The Kennedy framework would apply to standing Medicare/Medicaid coverage outside the demonstration.

What if I'm already using a continuous glucose monitor?

Under a step-therapy framework, documented prior CGM use would likely count toward the "exhausted other options" threshold. Your prescribing physician would note it in your records. This is how step therapy works in commercial insurance today.

Will TrumpRx GLP-1 pricing be affected?

No. The TrumpRx Most-Favored-Nation deal is a direct-to-patient program. It bypasses insurance entirely, so step-therapy rules don't apply.

Sources